Trials / Completed
CompletedNCT00442897
Vytorin (10/20 Or 10/40) Compared to Atorvastatin (10 mg or 20 mg) in Patients With Coronary Artery Disease (0653A-126)(COMPLETED)
Evaluate The Lipid-Lowering Efficacy and Safety of Vytorin in Comparison With Atorvastatin in Hypercholesterolaemic Patients With Coronary Artery Disease
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 229 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate the proportion of hyperlipaemic persons with known coronary heart disease achieving ldl-c goal as defined by the national cholesterol education program (NCEP) adult treatment panel (ATP) III guidelines
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | simvastatin (+) ezetimibe | simvastatin (+) ezetimibe 10/20mg, tablet, once daily, 12wks(sub group:24wks) |
| DRUG | Comparator: atorvastatin | atorvastatin 10mg, tablet, once daily, 12wks(sub group:24wks) |
Timeline
- Start date
- 2006-09-01
- Primary completion
- 2008-10-01
- Completion
- 2008-10-01
- First posted
- 2007-03-05
- Last updated
- 2024-05-22
- Results posted
- 2009-11-09
Source: ClinicalTrials.gov record NCT00442897. Inclusion in this directory is not an endorsement.